Electrocorticography (ECoG) has been demonstrated as a promising neural signal source for developing brain-machine interfaces (BMIs). However, many concerns about the disadvantages brought by large craniotomy for implanting the ECoG grid limit the clinical translation of ECoG-based BMIs. In this study, we collected clinical ECoG signals from the sensorimotor cortex of three epileptic participants when they performed hand gestures. The ECoG power spectrum in hybrid frequency bands was extracted to build a synchronous real-time BMI system. High decoding accuracy of the three gestures was achieved in both offline analysis (85.7%, 84.5%, and 69.7%) and online tests (80% and 82%, tested on two participants only). We found that the decoding performance was maintained even with a subset of channels selected by a greedy algorithm. More importantly, these selected channels were mostly distributed along the central sulcus and clustered in the area of 3 interelectrode squares. Our findings of the reduced and clustered distribution of ECoG channels further supported the feasibility of clinically implementing the ECoG-based BMI system for the control of hand gestures.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605870PMC
http://dx.doi.org/10.1155/2017/3435686DOI Listing

Publication Analysis

Top Keywords

ecog signals
8
sensorimotor cortex
8
hand gestures
8
bmi system
8
ecog
6
gesture decoding
4
decoding ecog
4
signals human
4
human sensorimotor
4
cortex pilot
4

Similar Publications

The precise localization of epileptic foci with the help of EEG or iEEG signals is still a clinical challenge with current methodology, especially if the foci are not close to individual electrodes. On the research side, dipole reconstruction for focus localization is a topic of recent and current developments. Relatively low numbers of recording electrodes cause ill-posed and ill-conditioned problems in the inversion of lead-field matrices to calculate the focus location.

View Article and Find Full Text PDF

Efficacy of Ruxolitinib in the management of chronic GVHD.

Transfus Apher Sci

December 2024

University of Health Sciences, Ankara Oncology Training and Research Hospital, Department of Hematology & Apheresis Unit, Ankara, Turkey; Ankara Yildirim Beyazit University, School of Medicine, Department of Internal Medicine, Division of Hematology, Ankara, Turkey.

Objectives: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment for hematological diseases, with success rates improving due to advancements in conditioning regimens and new anti-graft versus host disease (GVHD) drugs. Ruxolitinib, an oral selective Janus kinase (JAK) 1 and 2 inhibitor has been used to mitigate the effects of various inflammatory and myeloproliferative syndromes, given the JAK kinase pathway's central role in cytokine signaling during inflammatory and immune processes. In this study we aimed to assess ruxolitinib's efficacy in patients with chronic GVHD (cGVHD).

View Article and Find Full Text PDF

Cooperative interactions profoundly shape individual and collective behaviors of social animals. Successful cooperation requires coordinated efforts by cooperators toward collective goals. However, the underlying behavioral dynamics and neuronal mechanisms within and between cooperating brains remain largely unknown.

View Article and Find Full Text PDF
Article Synopsis
  • Enfortumab vedotin (EV) is a new treatment option for patients with advanced urothelial carcinoma who haven't responded to other therapies.
  • A study involving 128 patients in Austria showed an objective response rate of 31%, with median progression-free survival of 4.8 months and overall survival of 10.75 months.
  • The treatment was found to be feasible and effective, with an acceptable safety profile, although lower efficacy was noted compared to earlier trials, likely due to the patient population being in later therapy lines.
View Article and Find Full Text PDF

Purpose: The NCI-MATCH study is a tumor-agnostic platform trial enrolling patients to targeted therapies on the basis of genomic alterations. Subprotocol V investigated sunitinib in patients with tumors harboring - mutations.

Methods: EAY131-V, is an open-label, single-arm, phase II study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!